查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2002886

神经病变疼痛治疗​​市场：依治疗方法、给药途径、通路和最终用户划分－2026-2032年全球市场预测

Neuropathy Pain Treatment Market by Treatment Type, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，神经病变疼痛治疗​​市场价值将达到 95.3 亿美元，到 2026 年将成长至 105.7 亿美元，到 2032 年将达到 211.8 亿美元，复合年增长率为 12.08%。

主要市场统计数据
基准年 2025 95.3亿美元
预计年份：2026年 105.7亿美元
预测年份 2032 211.8亿美元
复合年增长率 (%) 12.08%

神经病变疼痛应被视为一个复杂的临床和商业性生态系统，其中治疗方法、护理路径和患者期望相互交织，共同塑造治疗结果。

神经病变疼痛是一个涉及神经病学、疼痛管理、復健护理和患者自我管理等多方面的临床挑战。本文将神经病变疼痛视为一个生态系统，它不仅包含一系列症状，更涵盖了治疗方法、服务模式以及相关人员之间的互动，这些因素共同决定着患者的治疗结果和商业性机会。透过将临床实践、护理路径和分销管道置于一个连贯的叙事框架中，相关人员可以更好地评估治疗方案的适用性，并确定哪些领域的渐进式创新能够为患者和支付方创造最大价值。

神经调控、治疗、数位医疗和报销模式的进步如何重塑神经病变治疗的临床实践和商业性差异化。

神经病变治疗​​领域正经历着一场变革，其驱动力包括技术成熟、监管改革以及对个人化医疗的日益重视。神经调控技术的最新进展，特别是周边和脊髓刺激技术的改进，拓展了临床治疗手段，使其超越了传统药物疗法，从而能够进行更具针对性的干预，减少全身镇痛药物的暴露。同时，药物研发也努力改进抗惊厥药物和抗忧郁症的作用机制，优化神经病变疼痛讯号传导，同时最大限度地减少可能影响患者长期用药依从性的副作用。

对于神经病变疼痛治疗​​领域的相关人员，近期关税调整对供应链、生产决策和采购趋势的累积影响不容忽视。

源自于2025年贸易措施的关税政策变化，正对参与神经病变疼痛治疗​​的相关人员的采购、製造和定价策略产生累积影响。依赖跨境供应链采购医疗设备组件、电子子系统和特殊聚合物的製造商正面临不断上涨的进口成本，并被迫重新评估其在采购、库存缓衝和供应商多元化方面的运作。这些压力促使一些相关人员加快对国内製造的投资，或寻求对免税地区的替代供应商进行认证，以降低风险。

将治疗类型、途径、分销管道和医疗保健环境与实际实施途径和临床效用联繫起来的综合细分观点。

详细的细分观点对于理解神经病变疼痛管理中的治疗路径和相关人员动态至关重要。按治疗类型分类，其范围涵盖了多种疗法，包括草药补充剂和心身疗法等辅助疗法、神经调控和经皮神经电刺激（TENS）等器械疗法、从镇痛药到外用药等药物疗法，以及针灸、按摩和物理疗法等支持性疗法。在器械疗法中，神经调控又分为週边神经刺激和脊髓刺激，二者各自具有独特的机制和植入途径，进而影响临床诱导和追踪需求。同样，在药物细分方面，镇痛药分为非阿片类和阿片类，抗惊厥药主要分为加巴喷丁类，抗忧郁药分为选择性5-羟色胺和去甲肾上腺素再摄取抑制剂（SNRI）和三环类抗忧郁症（TCAs），而辣椒素和Lidocaine製剂等外用药也具有代表性。

美洲、欧洲、中东和非洲以及亚太地区在监管、支付方和基础设施方面的区域差异如何影响部署路径和存取策略？

区域趋势显着影响神经病变治疗中技术的应用、监管路径和报销框架。在美洲，临床实践和支付方框架都高度重视疗效比较和真实世界数据的生成，促进了实证神经调控技术和标靶药物疗法的快速应用。该地区还拥有成熟的专科诊所网络和完善的零售药房体系，这两者共同促进了医疗设备在诊所内的治疗以及口服和外用药物的广泛应用。

企业策略和竞争趋势正在加速医疗设备、药品和神经病变疼痛管理综合护理模式的创新。

企业层面的措施正在决定神经病变疼痛治疗​​领域创新和竞争优势的来源。领先的医疗设备製造商正投资于下一代神经调控平台，优先考虑小型化、简化植入流程和远端编程功能，旨在减轻后续治疗负担并扩大适用患者群体。中小型医疗技术公司则专注于特定适应症和差异化给药机制，在寻求合作伙伴以拓展业务和实现更广泛的商业化之前，专注于证明其临床疗效。

为产业领导者制定可操作的策略重点，以协调创新、供应链韧性、支付方合作和以患者为中心的护理，从而治疗神经病变疼痛。

产业领导者应采取多管齐下的策略，将产品创新、永续取得和以患者为中心的疗效相结合。首先，应优先开发推广微创神经调控技术，并简化植入流程，以降低手术复杂性，扩大潜在患者群。此外，应将设备创新与可互通的数位平台结合，实现远端程式设计、用药依从性追踪和病患报告结果收集，从而加强临床随访，并为支付方提供更多循证依据。

透过结合专家访谈、临床文献整合和资料检验的混合方法研究框架，我们提供可重复且与当地相关的见解。

本研究采用质性与量化结合的混合方法，为研究结果奠定了严谨的基础。第一阶段包括对临床医生、保险公司、医疗设备和製药公司高阶主管以及供应链专家进行结构化访谈，以了解他们对临床效用、推广障碍和采购趋势的实际观点。第二阶段则查阅了同侪审查的临床文献、监管申报文件、临床试验註册资讯、专利资料库和公共文件，以检验临床机制、安全性以及核准流程。

整合临床、商业性和营运方面的见解，以明确在神经病变治疗领域实现持久患者影响和永续市场领导地位的策略路径。

总之，神经病变疼痛的治疗模式正从以全身性药物治疗为主导的模式，转向整合神经调控疗法、优化药物、辅助疗法和数位化驱动的诊疗路径的多元化生态系统。这一转变受到技术创新、支付方期望变化以及应对全球供应链和贸易压力的营运措施的影响。将产品开发与实用交付模式、可靠的真实世界证据和稳健的供应链网络相结合的相关人员，将更有能力满足临床医生的期望和患者的需求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗方法分類的神经病变疼痛治疗​​市场

  • 辅助疗法
    • 草药补充剂
    • 身心疗法
  • 医疗设备
    • 神经调节
      • 週边神经刺激
      • 脊髓刺激疗法
    • TENS
  • 製药
    • 止痛药
      • 非阿片类药物
      • 阿片类药物
    • 抗惊厥药物
    • 抗忧郁症
    • 外用製剂
      • 辣椒素
      • Lidocaine
  • 治疗
    • 针刺
    • 按摩疗法
    • 物理治疗

第九章：神经病变疼痛治疗​​市场：依给药途径划分

  • 注射药物
    • 静脉
    • 皮下
  • 口服
    • 胶囊
    • 药片
  • 外用
    • 奶油
    • 凝胶
  • 经皮

第十章：神经病变疼痛治疗​​市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房
  • 专科诊所

第十一章：神经病变疼痛治疗​​市场：依最终用户划分

  • 门诊治疗
  • 诊所
  • 居家照护
  • 医院

第十二章：神经病变疼痛治疗​​市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：神经病变疼痛治疗​​市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：神经病变疼痛治疗​​市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国神经病变疼痛治疗​​市场

第十六章：中国神经病变疼痛治疗​​市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol Myers Squibb Company
  • DAIICHI SANKYO COMPANY, LIMITED
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International PLC
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson and Johnson Services, Inc.
  • Medtronic PLC
  • NeuroMetrix, Inc.
  • Nevro Corporation
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
Product Code: MRR-957C47F9180B

The Neuropathy Pain Treatment Market was valued at USD 9.53 billion in 2025 and is projected to grow to USD 10.57 billion in 2026, with a CAGR of 12.08%, reaching USD 21.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.53 billion
Estimated Year [2026] USD 10.57 billion
Forecast Year [2032] USD 21.18 billion
CAGR (%) 12.08%

Framing neuropathic pain as a complex clinical and commercial ecosystem where treatment modalities, care pathways, and patient expectations intersect to shape outcomes

Neuropathy pain represents a multifaceted clinical challenge that intersects neurology, pain management, rehabilitative care, and patient self-management. This introduction frames neuropathy not merely as a symptom complex but as an ecosystem of therapeutic approaches, delivery models, and stakeholder interactions that determine patient outcomes and commercial opportunity. By situating clinical modalities, care pathways, and distribution practices within one coherent narrative, stakeholders can better evaluate treatment fit and identify where incremental innovation yields the greatest patient and payer value.

Across clinical practice, neuropathic pain management increasingly requires integrated strategies that combine pharmacologic agents, neuromodulation devices, and supportive therapies. Clinicians and health systems are balancing efficacy, tolerability, and long-term safety while navigating regulatory and reimbursement constraints. Concurrently, patient expectations for minimally invasive interventions, rapid functional recovery, and clear pathways for home-based care are reshaping how treatments are developed, positioned, and delivered. This section sets the stage for subsequent analysis by emphasizing the interdependence of clinical evidence, device and drug innovation, care delivery channels, and patient-centered design.

How advances in neuromodulation, therapeutics, digital care, and reimbursement models are reshaping clinical practice and commercial differentiation in neuropathy treatment

The neuropathy treatment landscape is undergoing transformative shifts driven by technological maturation, regulatory recalibration, and a stronger emphasis on personalized care. Recent advances in neuromodulation-particularly improvements in peripheral nerve stimulation and spinal cord stimulation-have expanded the clinical toolkit beyond traditional pharmacotherapy, enabling more targeted interventions that can reduce systemic exposure to analgesics. At the same time, drug development is refining mechanisms of action within anticonvulsants and antidepressants to optimize neuropathic pain signaling while minimizing adverse effects that limit long-term adherence.

Beyond clinical innovations, shifts in care delivery are equally consequential. Digital health platforms and remote programming tools enable follow-up and titration of device therapies outside traditional clinic settings, reinforcing the trend toward home-based care and ambulatory interventions. Distribution channels are diversifying, with online pharmacies and specialty clinics playing an increasingly prominent role alongside hospital and retail pharmacies. Payer frameworks are evolving to emphasize outcomes and value-based contracting, prompting manufacturers to generate stronger real-world evidence and to negotiate bundled approaches that link device and therapy reimbursement to measurable patient improvements. Collectively, these transformative shifts are redefining competitive differentiators for companies operating in the neuropathy pain space.

The cumulative implications of recent tariff adjustments on supply chains, manufacturing decisions, and procurement dynamics for neuropathy treatment stakeholders

Tariff policy changes originating from trade actions in 2025 have had a cumulative effect across procurement, manufacturing, and pricing strategies for stakeholders involved in neuropathic pain interventions. Manufacturers that rely on cross-border supply chains for device components, electronic subsystems, and specialized polymers have faced higher landed costs for imports, prompting an operational reassessment of sourcing, inventory buffers, and supplier diversification. These pressures have led some stakeholders to accelerate domestic manufacturing investments or to qualify alternate suppliers in tariff-exempt jurisdictions to mitigate exposure.

On the pharmaceutical side, tariffs and import levies on intermediates and finished formulations have introduced additional cost variables for oral, injectable, and transdermal products. Manufacturers have responded by optimizing formulation workflows, consolidating production footprints, and exploring regulatory pathways for localized manufacturing to preserve margin stability and ensure supply continuity. Payers and health systems have reacted by placing greater scrutiny on procurement decisions, with an increased appetite for cost transparency and long-term contracts that can insulate budgets from episodic trade disruptions.

Clinicians and providers have also felt downstream impacts: specialty clinics and hospital pharmacies confronting higher acquisition costs are adjusting formularies and device inventories, while online and retail pharmacies reassess price competitiveness. The cumulative effect is a heightened focus on operational resilience across the value chain, accelerated efforts to secure predictable supply routes, and renewed emphasis on integrated care models that can justify premium therapies through documented clinical benefit and total cost of care improvements.

An integrated segmentation perspective that maps treatment types, routes, distribution channels, and care settings to practical adoption pathways and clinical utility

A nuanced segmentation view is essential to understand treatment pathways and stakeholder dynamics in neuropathic pain management. When organizing by treatment type, the landscape spans complementary approaches such as herbal supplements and mind-body techniques, device-based solutions including neuromodulation and transcutaneous electrical nerve stimulation, drug classes from analgesics through topical agents, and supportive therapies like acupuncture, massage, and physical therapy. Within device therapies, neuromodulation divides into peripheral nerve stimulation and spinal cord stimulation, each offering distinct mechanisms and implantation pathways that influence clinical adoption and follow-up requirements. Pharmaceutical segmentation likewise differentiates analgesics into non-opioids and opioids, anticonvulsants concentrated around gabapentinoids, antidepressants categorized into SNRIs and TCAs, and topical agents typified by capsaicin and lidocaine formulations.

Route of administration further stratifies therapeutic choice, with injectable options delivered either intravenously or subcutaneously for certain specialty agents, oral treatments formulated as capsules or tablets for ease of adherence, topical creams and gels for localized pain control, and transdermal patches for sustained dosing. Distribution channels mediate access and patient experience, with hospital pharmacies and specialty clinics providing controlled administration and device programming, retail pharmacies facilitating point-of-care dispensing, and online pharmacies offering ease of refill and broader geographic reach. End-user segmentation highlights care settings that shape treatment pathways and monitoring intensity, ranging from ambulatory care and clinics to home-based management and inpatient hospital environments.

Interpreting these intersecting dimensions reveals differential adoption drivers. Device therapies demand structured clinical pathways and post-procedure follow-up, favoring hospital and specialty clinic channels during the initial implantation phase before transitioning toward ambulatory and home-based management supported by remote monitoring. Oral and topical pharmacotherapies align with retail and online distribution for chronic maintenance, while injectables typically remain concentrated in clinic or hospital settings. Complementary and rehabilitative therapies integrate across all end-user settings and often serve as adjuncts that improve functional outcomes and patient satisfaction.

How regional regulatory, payer, and infrastructure differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape adoption pathways and access strategies

Regional dynamics materially influence technology adoption, regulatory pathways, and reimbursement paradigms for neuropathy treatments. In the Americas, clinical practice and payer frameworks are characterized by a strong emphasis on comparative effectiveness and real-world data generation, which supports rapid uptake of evidence-backed neuromodulation technologies and targeted pharmacotherapies. The region also exhibits mature specialty clinic networks and a well-developed retail pharmacy sector that together facilitate both in-clinic device procedures and broad access to oral and topical agents.

In Europe, Middle East & Africa, heterogeneity in regulatory regimes and reimbursement criteria affects the pace of product introduction and scaling. Several Western European systems emphasize cost-effectiveness evaluations and centralized procurement processes, while emerging markets within the region may prioritize affordability and operational simplicity, favoring lower-cost device iterations and locally manufactured formulations. MEA markets also present opportunities for decentralized care models that leverage clinic-based and ambulatory approaches to extend access where hospital capacity is constrained.

The Asia-Pacific region demonstrates a dual trend: rapid adoption of minimally invasive devices and digital health solutions in higher-income economies, paired with large-scale demand for cost-efficient pharmacologic and complementary treatments in developing markets. Local manufacturing capabilities, export-oriented supply chains, and active participation in regional regulatory harmonization efforts influence commercialization strategies. Across all regions, payer scrutiny, demographic shifts toward aging populations, and the growing prevalence of chronic conditions underscore the need for adaptable care models that balance clinical efficacy with access and affordability.

Company strategies and competitive moves that are accelerating innovation in devices, pharmaceuticals, and integrated care models for neuropathic pain management

Company-level activity is defining where innovation and competitive advantage will emerge in neuropathic pain treatment. Leading device manufacturers are investing in next-generation neuromodulation platforms that prioritize miniaturization, simplified implant workflows, and remote programming capabilities to reduce follow-up burden and broaden eligible patient populations. Smaller medtech firms are focusing on niche indications and differentiated delivery mechanisms to establish clinical proof points before scaling or partnering for broader commercialization.

Pharmaceutical companies are pursuing improved formulations and mechanism-specific agents that can complement device therapies or serve as safer chronic alternatives to systemic opioids. There is a growing trend towards strategic collaborations between device and drug developers to explore combination therapy models that couple targeted neuromodulation with optimized pharmacologic regimens. Commercial strategies increasingly incorporate value demonstration, with companies allocating resources to real-world evidence generation, payer engagement, and outcomes-based contracting pilots to secure formulary access and favorable reimbursement terms.

Across the competitive landscape, mergers, acquisitions, and cross-sector partnerships are reshaping portfolios and accelerating time-to-market for integrated solutions. Investment in service delivery models-such as clinic networks, remote monitoring services, and patient education platforms-has become a differentiator that extends beyond the product itself. Companies that harmonize clinical evidence, operational scalability, and payer-aligned value propositions will be best positioned to capture long-term clinical and commercial relevance in neuropathy treatment.

Actionable strategic priorities for industry leaders to align innovation, supply chain resilience, payer engagement, and patient-centered care in neuropathy treatment

Industry leaders should pursue a multifaceted strategy that links product innovation to durable access and patient-centered outcomes. First, prioritize development and deployment of minimally invasive neuromodulation technologies and streamlined implant workflows to reduce procedural complexity and broaden candidate pools. Complement device innovation with interoperable digital platforms that enable remote programming, adherence tracking, and patient-reported outcome capture, thereby strengthening clinical follow-up and payer-facing evidence portfolios.

Second, de-risk supply chains by diversifying suppliers, qualifying alternate manufacturing sites, and considering localized production for critical components and formulations. Such measures mitigate exposure to trade policy volatility and support continuity of care across geographies. Third, engage proactively with payers and health systems to co-design reimbursement approaches that link payment to demonstrated functional improvements and reduced total cost of care. Investing in real-world evidence programs and pragmatic outcome studies will accelerate reimbursement discussions and support value-based contracting.

Fourth, expand distribution strategies by integrating specialty clinic networks, retail pharmacy partnerships, and online pharmacy channels to match treatment modalities with appropriate care settings. Concurrently, strengthen patient education and clinician training programs to ensure proper device selection, optimized therapy titration, and improved adherence for pharmacologic treatments. Lastly, cultivate strategic alliances that combine the strengths of device makers, pharmaceutical firms, and service providers to develop bundled solutions that address the multifactorial nature of neuropathic pain and deliver holistic value to patients and payers.

A mixed-methods investigational framework combining expert interviews, clinical literature synthesis, and data triangulation to deliver reproducible and regionally informed insights

The research adopted a mixed-methods approach combining qualitative and quantitative techniques to provide a rigorous foundation for insights. Primary research included structured interviews with clinicians, payers, medtech and pharmaceutical executives, and supply chain specialists to capture frontline perspectives on clinical utility, adoption barriers, and procurement dynamics. Secondary research encompassed peer-reviewed clinical literature, regulatory filings, clinical trial registries, patent databases, and public policy documents to validate clinical mechanisms, safety profiles, and approval pathways.

Data triangulation ensured findings were cross-validated across independent sources, while thematic synthesis distilled practical implications for commercialization and care delivery. Geographic representation in the research design covered the Americas, Europe Middle East & Africa, and Asia-Pacific to reflect regulatory and payer variability. Limitations were explicitly documented, including evolving regulatory guidance and the variable maturity of real-world evidence across regions, and sensitivity checks were applied where data heterogeneity existed. The methodology prioritized transparency in source attribution and reproducibility of analytic steps to enable stakeholders to interrogate assumptions and adapt insights to organizational contexts.

Synthesis of clinical, commercial, and operational insights that delineate the strategic pathways to lasting patient impact and sustainable market leadership in neuropathy care

In conclusion, neuropathic pain treatment is transitioning from a paradigm dominated by systemic pharmacotherapy toward a more diversified ecosystem that integrates neuromodulation, optimized drugs, complementary therapies, and digitally enabled care pathways. This evolution is being shaped by technological innovation, shifting payer expectations, and operational responses to global supply chain and trade pressures. Stakeholders who align product development with pragmatic delivery models, robust real-world evidence generation, and resilient supply networks will be best placed to meet clinician expectations and patient needs.

Ultimately, the path to sustained clinical impact and commercial viability lies in delivering demonstrable functional improvements at the point of care while ensuring predictable access and affordability. Cross-sector collaboration, targeted investments in post-market data, and adaptive distribution strategies will determine which organizations emerge as leaders in the neuropathic pain arena. This report's insights are intended to support strategic decisions that bridge clinical promise and practical implementation across diverse health systems and care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuropathy Pain Treatment Market, by Treatment Type

  • 8.1. Complementary
    • 8.1.1. Herbal Supplements
    • 8.1.2. Mind Body Techniques
  • 8.2. Device
    • 8.2.1. Neuromodulation
      • 8.2.1.1. Peripheral Nerve Stimulation
      • 8.2.1.2. Spinal Cord Stimulation
    • 8.2.2. TENS
  • 8.3. Drug
    • 8.3.1. Analgesics
      • 8.3.1.1. Non-Opioids
      • 8.3.1.2. Opioids
    • 8.3.2. Anticonvulsants
    • 8.3.3. Antidepressants
    • 8.3.4. Topical Agents
      • 8.3.4.1. Capsaicin
      • 8.3.4.2. Lidocaine
  • 8.4. Therapy
    • 8.4.1. Acupuncture
    • 8.4.2. Massage Therapy
    • 8.4.3. Physical Therapy

9. Neuropathy Pain Treatment Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Tablets
  • 9.3. Topical
    • 9.3.1. Creams
    • 9.3.2. Gels
  • 9.4. Transdermal

10. Neuropathy Pain Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy
  • 10.4. Specialty Clinic

11. Neuropathy Pain Treatment Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Clinic
  • 11.3. Home Care
  • 11.4. Hospital

12. Neuropathy Pain Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neuropathy Pain Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neuropathy Pain Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Neuropathy Pain Treatment Market

16. China Neuropathy Pain Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Amgen Inc.
  • 17.8. Astellas Pharma Inc.
  • 17.9. AstraZeneca PLC
  • 17.10. Aurobindo Pharma Limited
  • 17.11. Baxter International Inc.
  • 17.12. Bayer AG
  • 17.13. Biogen Inc.
  • 17.14. Boehringer Ingelheim International GmbH
  • 17.15. Boston Scientific Corporation
  • 17.16. Bristol Myers Squibb Company
  • 17.17. DAIICHI SANKYO COMPANY, LIMITED
  • 17.18. Dr. Reddy's Laboratories Ltd.
  • 17.19. Eli Lilly and Company
  • 17.20. Endo International PLC
  • 17.21. GlaxoSmithKline PLC
  • 17.22. H. Lundbeck A/S
  • 17.23. Johnson and Johnson Services, Inc.
  • 17.24. Medtronic PLC
  • 17.25. NeuroMetrix, Inc.
  • 17.26. Nevro Corporation
  • 17.27. Novartis AG
  • 17.28. Pfizer Inc.
  • 17.29. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROPATHY PAIN TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HERBAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HERBAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HERBAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MIND BODY TECHNIQUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MIND BODY TECHNIQUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MIND BODY TECHNIQUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PERIPHERAL NERVE STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PERIPHERAL NERVE STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PERIPHERAL NERVE STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPINAL CORD STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPINAL CORD STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPINAL CORD STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NON-OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NON-OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CAPSAICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CAPSAICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CAPSAICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY LIDOCAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY LIDOCAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MASSAGE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MASSAGE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MASSAGE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 273. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 274. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 275. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 276. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 277. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 278. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 281. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 283. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. GCC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NEUROMODULATION, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANALGESICS, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COMPLEMENTARY, 2018-2032 (USD MILLION)
  • TABLE 318. G7 NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DEVI